6769152
Last Update Posted: 2025-03-04
Recruiting
Females accepted | 18 Years-75 Years |
60 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic CC Failed or Intolerance to Standard Therapy
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic Cervical Cancer (CC) Failed or Intolerance to Standard First-Line Therapy.
This study is an open-label phase II clinical study to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic Cervical Cancer (CC) Failed or Intolerance to Standard First-Line Therapy.
In this study, eligible subjects will be randomized at 1:1:1 ratio, and the patients will be administered with HLX43 at different doses via intravenous infusion.
Eligibility
Relevant conditions:
Cervical Cancers
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
No valid contacts available
Data sourced from ClinicalTrials.gov